A retrospective study of infants with severe persistent pulmonary hypertension (PPHN) managed without extracorporeal membrane oxygenation (ECMO)

Ann Acad Med Singap. 1998 May;27(3):366-70.

Abstract

We studied 13 consecutive infants admitted to our Neonatal Intensive Care Unit over 37 months from 1 June 1994 to 30 June 1997, who were diagnosed with severe persistent pulmonary hypertension (PPHN) meeting extracorporeal membrane oxygenation (ECMO) criteria as defined by Bartlett and/or Short. They were managed with conservative ventilation strategy, with emphasis on the use of moderate ventilatory pressures whilst avoiding paralysis. Peak inspiratory pressure (PIP) on intermittent mandatory ventilation was adjusted according to adequate chest excursion. High PIP was avoided. Two main ventilatory techniques were used: 1) low ventilatory rate < or = 40/min, PIP 20 to 30 cmH2O, inspiratory time (IT) 0.5 seconds, positive end-expiratory pressure (PEEP) 5 cmH2O, and 2) high ventilatory rate 100/min, PEEP 0 cmH2O, IT 0.3 seconds. The aim was to keep preductal PaO2 > or = 50 mmHg. We did not sought to achieve alkalotic pH or low PaCO2. When PIP requirements exceeded 30 to 35 cmH2O, the use of an alternative rescue therapy such as pulmonary vasodilator, high frequency ventilation and/or surfactant were considered. Only 1 infant died of PPHN. Low mortality due to PPHN can be achieved using this strategy. There is a need for a randomised controlled trial to compare this strategy with other alternative treatment strategies.

MeSH terms

  • Acid-Base Equilibrium
  • Antihypertensive Agents / therapeutic use
  • Apgar Score
  • Extracorporeal Membrane Oxygenation / adverse effects
  • Female
  • Humans
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Male
  • Persistent Fetal Circulation Syndrome / diagnosis
  • Persistent Fetal Circulation Syndrome / mortality
  • Persistent Fetal Circulation Syndrome / therapy*
  • Positive-Pressure Respiration
  • Prognosis
  • Respiration, Artificial
  • Retrospective Studies
  • Singapore
  • Survival Rate
  • Treatment Outcome

Substances

  • Antihypertensive Agents